Abstract C160: Baseline characteristics, safety, and efficacy of Radium-223 in metastatic castration resistant prostate cancer by race: Insights from the REASSURE US subset

Authors

Celestia S. Higano (ORCID: https://orcid.org/0000-0001-5308-8972)
Robert K. Brookland
Mary‐Ellen Taplin (ORCID: https://orcid.org/0000-0002-3384-0300)
Richard Andrés
Svetlana Babajanyan (ORCID: https://orcid.org/0000-0002-5910-5988)
C.A. Mantz (ORCID: https://orcid.org/0000-0003-3107-6705)
Jeffrey Tomaszewski (ORCID: https://orcid.org/0000-0001-8415-2535)
Daniel Y. Song (ORCID: https://orcid.org/0000-0002-3495-8677)
John Sylvester (ORCID: https://orcid.org/0000-0002-6543-2934)
Matthew J. Korn
Oliver A. Sartor (ORCID: https://orcid.org/0000-0002-8777-7343)
Saby George (ORCID: https://orcid.org/0000-0002-0444-5870)
Robert W Given
Peter S. Conti
Jeff Meltzer

Institutions

Tulane University (US)
Roswell Park Comprehensive Cancer Center (US)
Johns Hopkins University (US)
Bayer (United States) (US)
Eastern Virginia Medical School (US)
University of Washington (US)
Johns Hopkins Medicine (US)
Fred Hutch Cancer Center (US)
USC Norris Comprehensive Cancer Center (US)
Dana-Farber Cancer Institute (US)
MemorialCare Health System (US)
Chesapeake Urology Associates (US)

Publication Details

Journal: Cancer Epidemiology Biomarkers & Prevention
Published: 2024-09-21
DOI: https://doi.org/10.1158/1538-7755.disp24-c160
Primary Topic: Radiopharmaceutical Chemistry and Applications
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Abstract C160: Baseline characteristics, safety, and efficacy of Radium-223 in metastatic castration resistant prostate cancer by race: Insights from the REASSURE US subset

Celestia S. Higano, Robert K. Brookland, Mary‐Ellen Taplin, Richard Andrés et al.

Sep 21, 2024

Cancer Epidemiology Biomarkers & Prevention

Radiopharmaceutical Chemistry and Applications

article

Abstract C160: Baseline characteristics, safety, and efficacy of Radium-223 in metastatic castration resistant prostate cancer by race: Insights from the REASSURE US subset

Celestia S. Higano, Robert K. Brookland, Mary‐Ellen Taplin, Richard Andrés, Svetlana Babajanyan, C.A. Mantz, Jeffrey Tomaszewski, Daniel Y. Song, John Sylvester, Matthew J. Korn, Oliver A. Sartor, Saby George, Robert W Given, Peter S. Conti, Jeff Meltzer

September 21, 2024article en

Abstract

No abstract available for this paper.

Cancer Epidemiology Biomarkers & PreventionVol. 33(9_Supplement)

Tulane University (US), Roswell Park Comprehensive Cancer Center (US), Johns Hopkins University (US), Bayer (United States) (US), Eastern Virginia Medical School (US), University of Washington (US), Johns Hopkins Medicine (US), Fred Hutch Cancer Center (US), USC Norris Comprehensive Cancer Center (US), Dana-Farber Cancer Institute (US), MemorialCare Health System (US), Chesapeake Urology Associates (US)

Good health and well-being

Openalex Percentile: Top 73%

Radiopharmaceutical Chemistry and Applications

DOI Source OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Abstract C160: Baseline characteristics, safety, and efficacy of Radium-223 in metastatic castration resistant prostate cancer by race: Insights from the REASSURE US subset — Celestia S. Higano, Robert K. Brookland, et al. · Cancer Epidemiology Biomarkers & Prevention (2024) | TGRS Research Map | TGRS